Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site
May 06 2024 - 3:00AM
Business Wire
Kindeva Drug Delivery (Kindeva), a global leader in drug-device
combination products, today announced its investment in a second
manufacturing line for the production of pressurized metered-dose
inhaler (pMDI) products containing low-GWP (Global Warming
Potential) propellants in its Loughborough, U.K., facility.
This new line will be capable of handling both HFA-152a and
HFO-1234ze propellants — that have a GWP of 90% and 99.9% lower
than the industry standard HFA-134a, respectively — and is
anticipated to be operational in 2026. Kindeva’s first pMDI
manufacturing line, which was announced in 2022, is in its
installation phase and will be completed later in 2024.
Milton Boyer, Kindeva’s CEO said: “This investment will bring to
the market one of the first large-volume commercial green
propellant lines to the contract manufacturing market capable of
supplying up to 50 million pMDI units per year. This second
investment in low-GWP GMP manufacturing capacity further
underscores Kindeva’s commitment to enable the pharmaceutical
industry to meet its sustainability goals, whilst ensuring patient
choice is not compromised. With our first GMP low-GWP manufacturing
line expected to be operational in 2024, we are proud to be leading
the transition to low-GWP propellants by ensuring the capacity is
available.”
The new manufacturing line meets an increased customer demand
for more sustainable pMDI products and considers the recent
adoption of F-gas legislation in the European Union. Phase down of
the existing propellants will commence in 2027 in the EU and be
completed by the end of 2029.
Boyer continued: “With a track record of nearly 70 years in
pMDIs — including the invention of the pMDI in 1956 and leading the
CFC- to HFA-inhaler transition in the 1990s — we are excited to be
a part of this industry-wide switch in the pMDI space. Kindeva is
doing everything we can to ensure a greener future for all
stakeholders by doubling down on our commitment to the low-GWP
evolution.”
This announcement marks a continuation in the next chapter of
Kindeva’s leadership in driving sustainable innovation in pMDIs
and, more broadly, complex drug and combination products.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development and
manufacturing organization focused on drug-device combination
products. We develop and manufacture products across a broad range
of drug-delivery formats, including pulmonary & nasal,
injectable, and transdermal. Our service offerings span early-stage
feasibility through commercial scale drug product fill-finish,
container closure system manufacturing, and drug-device product
assembly. Kindeva serves a global client base from our
state-of-the-art manufacturing, research, and development
facilities located across the U.S. and U.K.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502795839/en/
Lindsey Langemeier +1 402-405-4269 pr@scorrmarketing.com